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Abstract
The late-onset sporadic type of Alzheimer’s disease is characterised by chronic 
oxidative stress, neuroinflammation and cognitive dysfunction. Ellagic acid is a 
naturally occurring polyphenol known to possess robust antioxidant property. In 
the present study, memory enhancing potential of ellagic acid has been explored 
against ICV colchicine induced dementia in rats.
Colchicine (15µg/rat) was administered to Wistar rats (200g) through 
intracerebroventricular (ICV) route by using stereotaxic apparatus. ICV 
colchicine induces Alzheimer’s disease like changes in the brain such as rampant 
free radical production, neuroinflammation and selective neurodegeneration in 
hippocampus and cortex by acting as an antitubulin agent (mitotic poison). 
Ellagic acid (17.5 and 35 mg/kg, p.o.) was administered to rats for 25 
successive days. Morris water maze and elevated plus maze paradigms were 
utilized to assess the spatial memory of rats. Oxidative stress biomarkers along 
with TNF-α were also measured in brain of rats. 
Ellagic acid prevented the ICV colchicine triggered cognitive deficits as evident 
by a significant (p<0.05) reduction in mean escape latency during acquisition 
trial and increased (p<0.05) time spent in target quadrant during probe trial in 
Morris water maze test, and reduction (p<0.05) in transfer latency in elevated 
plus maze test. Furthermore, both the doses of ellagic acid attenuated ICV 
colchicine induced rise in brain TBARS as well as TNF-α and simultaneously 





Ellagic acid prevented the brain of rodents from dementing effects of colchicine 
by attenuating the oxidative damage.
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1. INTRODUCTION
Alzheimer’s disease (AD) is a frequently occurring form of dementia, especially 
in old-aged persons, manifesting progressive neurodegeneration and severe 
memory loss (31). Atkinson and Shiffrin (1968) organised the brain memory 
functions into sensory memory, long- and short-term memory characterised 
as declarative and non-declarative, and working memory respectively. Both 
long-term and working/short-term memory are adversely affected in AD due 
to neurodegeneration in their associated structures. Medial temporal lobe 
memory (MTL) system maintains the declarative memory (explicit) while 
other cortical, subcortical and cerebellar structures regulate the non-declarative 
(implicit) memory (37). The consolidation of long-term memory takes place 
in neocortex whose retrieval after some time of learning becomes independent 
of MTL system. The hippocampus and frontal cortex integrity is vital for 
working memory (10). Loss of declarative memory (episodic and semantic 
both) in early stages and non-declarative memory failure in later stages leads 
to aphasia, agnosia, apraxia, agraphia, loss of visuospatial ability, reasoning, 
skills and behaviour changes in AD patients (41). Further, the pioneer studies on 
working memory by Baddeley and Hitch (1974) demonstrated that the ‘central 
executive component’ governs optimum functioning of working memory by 
regulating phonological loop, episodic buffer and visuospatial sketchpad (3). 
The end periods of AD portray gross atrophy in hippocampus and cerebral 
cortex along with enlargement of ventricles (33). The histopathology of AD 
describe archetypal neurofibrillary tangles and neuritic plaques originating 
in MTL memory system which spread to neocortex after a few years, duly 
accompanied by loss of cholinergic function in nucleus basalis (5). NFTs are 
intracellular deposits of hyperphosphorylated tau protein whereas extracellular 
plaques contain amyloid-β fibrils.
Eberus Papyrus (1500 BC), De Materia Medica (Pedanius Dioscorides; AD 
1) and Therapeutica (Alexander of Tralles; AD 6) have descriptions regarding 
the use of colchicum (Colchicum autumnale L.) rheumatism and gouty arthritis 
(11, 12). Colchicine is an antitubulin agent which disrupts microtubular 
assembly thereby causes apoptotic and necrotic neurodegeneration in selective 
brain regions viz. hippocampus and cortex (25). Previous studies have 
illustrated that administration of colchicine through intracerebroventricle 







stress and inflammation (4, 18, 13, 14, 15, 16). ICV colchicine augments 
production of chemically reactive molecules containing oxygen also termed as 
ROS, reactive nitrogen species (RNS), cycloxygenase-2 (COX-2), inducible 
nitric oxide synthase (iNOS) and enhance glutamatergic neurotoxicity. The 
cholinergic functions (thoughts, memory, intelligence and behaviour) of brain 
are severely disrupted by colchicine by causing neurodegeneration in nucleus 
basalis of Meynert in substantia innominata of basal forebrain (9, 21). The 
autopsy of AD brains revealed selective neurodegeneration in nucleus basalis 
in substantia innominata (42, 43). 
Ellagic acid is a polyphenolic hydrolytic product of ellagitannins 
(punicalagin, sanguiin-H6, pedunculagin) abundantly found in pomegranate, 
berries, nuts, wines and many spirits. It is known to possess several 
pharmacological properties such as antioxidant, antiinflammatory, 
antimicrobial, antidiarrheal and immunomodulatory (20). The cardioprotective 
property of ellagic acid and its sources has been extensively investigated during 
pre-clinical as well as clinical studies; and is attributed to anti-angiogenic, 
anti-atherogenic, vasodilatory, hypoglycaemic, hypocholesterolemic, anti-
adipogenic, anti-platelet and serum lipid profile improving activities (39). 
The pharmacokinetic studies revealed good absorption of ellagic acid (but not 
ellagitannins) from stomach and duodenum attaining C
max
 after 1 h (20). The 
digestion of ellagic acid begins in small intestine, where variety of enzymes 
contribute to its metabolism via phase I and phase II reactions, i.e. hydroxylation 
and glucuronidation respectively, in liver and plasma, eliminating majority of 
metabolites (urolithins) through urine (19). Based on the above discussed facts, 
we take on to analyse the therapeutic effect of ellagic acid in a colchicine-
promoted oxidative stress and inflammation in rat brains. 
2. MATERIALS AND METHODS
2.1 Animal selection
Adult Wistar rats (either sex), weighing between 180-200 g were obtained from 
the Disease Free Small Animal House, Lala Lajpat Rai University of Veterinary 
and Animal Science, Hisar. The animals were acclimatized for seven days to 
the housing conditions of Central Animal Facility of ASBASJSM College of 
Pharmacy, Bela prior to experiments. Animals were kept in polypropylene 
cages, and husk (free from any dust) was used for bedding in the cages. In 
additions, controlled temperature (23±2°C), humidity (40±10 %) and natural 
(12 h each) light-dark cycle was maintained for animals. The animal diet 
was standard rodent pellet diet (Ashirwad Industries, Mohali) and water ad 





research protocol of this study has been approved by IAEC and in laboratory, 
the animals were handled following the guidelines of CPCSEA, Ministry of 
Forests and Environment and Government of India.
2.2 Drugs and chemicals
Ellagic acid procured from Himedia laboratories, Mumbai was suspended 
in 0.1% gum acacia maintaining the temperature 40-50°C and pH 5-8. 
Colchicine, dihydrogen orthophosphate, 5,5′-Dithiobis(2-nitrobenzoic acid) 
(DTNB) (Himedia Laboratories, Mumbai); thiobarbituric acid, trichloroacetic 
acid, sodium dodecyl sulphate  (Loba Chemie, Mumbai); TNF-α ELISA kit 
(Krishgen, Mumbai) were used. Artificial cerebrospinal fluid (aCSF) was 
prepared as following: (In mmol/l) 147 mM NaCl, 2.9 mM KCl, 1.6 mM 
MgCl
2
, 1.7 mM CaCl
2
, 2.2 mM dextrose was dissolved in 10 ml of water for 
injection (17). The similar electrolytic concentration and osmolality of aCSF 
and authentic cerebrospinal fluid prompted utilisation of aCSF as solvent for 
intracerebroventricle (ICV) administration of drugs. All the drug solutions 
were freshly prepared before injections.
2.3 Intracerebroventricular injection of colchicine (ICV colchicine) 
The rats were anaesthetized with chloral hydrate (300 mg/kg, i.p.). The head 
was positioned in the frame of stereotaxic apparatus (INCO, Ambala, India), 
skull was exposed and middle saggital incision was made in the scalp. Two 
holes were drilled though the skull for bilateral placement of microinjector 
into the lateral cerebral ventricles using the following coordinates: 0.8 mm 
posterior to bregma, 1.5 mm lateral to saggital suture and 3.6 mm beneath 
the surface of the brain (29). Colchicine (15 µg/rat) was dissolved in freshly 
prepared aCSF (5 µl) and slowly injected (rate of injection 1 µl/min) though 
the cerebral ventricle (18, 14). Surgical control animals were given same 
volume of aCSF only. After surgery the skin of all the animals was sutured and 
antiseptic powder was applied.
2.4 Experimental protocol 
Ellagic acid (17.5 and 35 mg/kg, p.o.) was administered once daily to separate 
groups of rats for 28 consecutive days beginning 4 days prior to colchicine 
injection (Figure 1) (6). Intracerebroventricle (ICV) injection of colchicine 
was given to induce memory impairment. The rats were divided into 09 
different groups (6-8 rats in each group): Group I, Normal control (0.1% gum 
acacia for 25 days, p.o.); Group II, EGA(17.5) per se, ellagic acid (17.5 mg/







25 days, p.o.); Group IV, donepezil per se (1 mg/kg for 25 days, p.o.); Group 
V, ICV colchicine (15 µg/5 µl/rat on day 5, ICV); Group VI, sham control 
(aCSF 5 µl on day 5, ICV); Group VII, colchicine+EGA(17.5), ellagic acid 
(17.5 mg/kg for 25 days, p.o.) + colchicine (15 µg/5 µl/rat on day 5, ICV); 
Group VIII, colchicine+EGA(35), ellagic acid (35 mg/kg for 25 days, p.o.) + 
colchicine (15 µg/5 µl/rat on day 5, ICV); Group IX, colchicine+donepezil, 
donepezil (1 mg/kg for 25 days, p.o.) + colchicine (15 µg/5 µl/rat on day 5, 
ICV). Morris water maze (MWM) and elevated plus maze (EPM) tests were 
employed to measure the spatial memory of rats. On 21st day the rats were 
exposed to training sessions in MWM after 30 min of administration of ellagic 
acid and mean escape latency (MEL) is noted for four consecutive days. On 
25th day the time spent in the target quadrant (TSTQ) was noted. The EPM 
studies were carried out on 24th and 25th day for measurement of mean transfer 
latency (TL). The locomotor activity of animals was also measured before 
surgery and before behavioural studies. Donepezil (1 mg/kg, p.o.) served as 
the standard drug (36). After behavioural studies, the animals were sacrificed 
by decapitation to estimate brain TBARS, GSH and TNF-α level.
2.5 Exteroceptive behavioural models
2.5.1 Morris water maze test 
Morris water maze test was performed to test spatial learning and reference 
memory of the animals. Spatial learning is measured across repeated training 
trials (day 1 to 4) and reference memory is gauged during probe trial (on day 
5) by preference of rats for the platform area / quadrant when the platform is 
absent. MWM is a swimming based model, in which the test animal learns to 
escape on to a hidden platform. The model is composed of a large circular pool 





(200 cm in diameter, 60 cm in height, filled to a depth of 30 cm with water at 
25±1°C). The tank was divided, with the help of two threads, into four equal 
quadrants fixed at right angle to each other on the rim of pool. A submerged 
platform (11 cm2) was placed inside target quadrants of this pool at about 1 
cm beneath water surface. The position of platform was not disturbed during 
whole training session. 
Acquisition trial: at inter-trial gap of minutes, each animal was subjected to 
four successive training trials per day. Each animal (rat) was placed in water 
pool, between quadrants, facing wall, with change of drop location in each 
individual trial [Chart 1]. Thereafter, the animal was allowed for 120 s to trace 
submerged platform, and once identified, it was allowed to be at this for 20 
s. In case, animal failed to locate the submerged platform within 120 s, was 
manually guided towards platform, and allowed to stay there (at platform) 
for 20 s. Herein, the Escape latency time (ELT) is considered as time period 
availed by animal to discover hidden submerged platform in water maze. Day 
4 ELT vs day 1 ELT was noted as index of acquisition or learning. 
Chart 1: Morris water maze training trials chart
Day Quadrant for rat
Day 1 Q 1 Q 2 Q 3 Q 4
Day 2 Q 2 Q 3 Q 4 Q 1
Day 3 Q 3 Q 4 Q 1 Q 2
Day 4 Q 4 Q 1 Q 2 Q 3
Retrieval (Probe) trial: On 5thday of probe trial, submerged platform was 
removed and each animal was permitted to explore the pool for 120 s. 
Then, in all four quadrants, the mean time spent was observed. Thereafter, 
the average time taken by each animal in target quadrant (TSTQ) to locate 
the submerged platform was considered as index of memory or retrieval. 
The person performing experiment always attained similar position, and in 
addition, utmost care was ensured for relative location of water mazein respect 
to laboratory surroundings, so that the visual indications for animal were 
constant during whole period of experiment (18, 24). 
2.5.2 Elevated plus maze test 
The EPM apparatus (for rats)is comprised of a main central platform (10×10 
cm), which is further linked with two open (50×10 cm) and enclosed arms 







latency (TL) is considered as time span taken by rat to get into an enclosed 
arm, starting from an open arm, with all of its paws inside. For this, each rat 
was placed at the end of open arm, facing away from central platform. TL was 
recorded for each animal on their first, and they were permitted to discover 
the maze for 20 s. Finally, they were returned to their home cage. The cut off 
time to explore enclosed arm, starting from an open arm, was set to 90 s. If, 
in case, the rat was unable to discover the enclosed arm within cut off time, it 
was softly directed to any of enclosed arm. Retention of this learned task was 
examined 24 h after the first day trial (13).
2.5.3 Locomotor activity 
The locomotor activity was noted using actophotometer (INCO, Ambala, 
India) for a period of 5 min. Animal was placed in the actophotometer for 
habituation (3 min). The animals were then observed for 5 min and expressed 
as counts per 5 min (17).
2.6 Biochemical studies
2.6.1 Preparation of brain homogenate 
After behavioural study, the animals were sacrificed by decapitation. The brains 
were isolated and placed on ice followed by rinsing with ice-cold isotonic 
saline (0.9% NaCl). A (10% w/v) brain homogenate was prepared in 0.1mM 
phosphate buffer (pH 7.4), and centrifuged at 10,000 g for 15 min. Thereafter, 
the supernatant was used for biochemical estimation.
2.6.2 Measurement of brain TBARS 
Thiobarbituric acid reactive substances (TBARS) assay measures the lipid 
peroxidation product malondialdehyde (MDA) in tissue sample (26). The 
absorbance of supernatant was noted at 532 nm employing double beam UV-
Visible spectrophotometer (Shimadzu).
2.6.3 Measurement of reduced glutathione 
Reduced GSH was measured as per literature method (8), and absorbance was 
noted at 412 nm using double beam UV-Visible spectrophotometer.
2.6.4 Determination of TNF-α 
TNF-α value was measured as per the instructions given on the immunoassay 
kit. The absorbance was noted at 450 nm using ELISA reader (BIORAD).
2.7 Statistical analysis 
All the results are stated as mean ± SEM, and all group’s data was analysed 





of software Graph Pad InStat (Graph Pad Software Inc., USA). A value of 
p<0.05 was considered to be significant.
3. RESULTS
Ellagic acid and ICV colchicine treatments did not affected the locomotor 
activity of rats. There was insignificant statistical differences (p>0.05) in 
locomotion between the normal control and drug treated groups of rats as 
observed in actophotometer.
3.1 Effect of ellagic acid on learning and memory performance of rats in 
Morris water maze task
The normal control and sham control group rats displayed spatial learning by 
virtue of training during acquisition trials as evident by reduction (p<0.05) of 
day 4 MEL relative to day 1 MEL. Ellagic acid per se (17.5 and 35 mg/kg, 
p.o.) treated rats showed reduction of day 4 MEL (p<0.05) as compared to 
normal control group rats which indicates enhanced learning. ICV colchicine 
enhanced (p<0.05) day 4 MEL relative to sham control rats denoting profound 
learning impairment during training trials. However, ellagic acid treatment 
decreased the day 4 MEL (p<0.05) of colchicine treated rats. The standard 
nootropic drug donepezil considerably shortened (p<0.05) the day 4 MEL of 
rats during acquisition trials [Figure 2].  
In probe trial, it was observed that the ICV colchicine treatment 
reduced the TSTQ (p<0.05) of rats significantly as compared to normal 
control as well as sham control rats. But ICV colchicine induced decline 
in TSTQ value was arrested by administration of ellagic acid. However, 
ellagic acid per se group rats showed insignificant (p>0.05) elevation in 
TSTQ value in comparison to normal control rats. Furthermore, donepezil 
comprehensively enhanced the TSTQ value in colchicine treated rats 
[Figure 2].
3.2 Effect of ellagic acid on memory performance of rats in elevated plus 
maze paradigm
Ellagic acid per se group rats displayed reduction in TL (p<0.05) relative to 
rats of normal control group. ICV colchicine treatment increased (p<0.05) the 
TL value of rats relative to sham and normal control group values. However, 
administration of ellagic acid abolished the increase in TL (p<0.05) value of 
colchicine-treated rats [Figure 3]. A decrease in TL (p<0.05) of donepezil 







Figure 2: Effect of ellagic acid on spatial learning (day 4 vs. day 1 MEL) 
and reference memory (TSTQ) of rats during acquisition trials and retrieval 
trial respectively in Morris water maze task. [Values are expressed as mean ± 
SEM (n = 6-8), Significance at p<0.05, aversus respective day 1 MEL, bversus 
normal control, cversus sham control group and dversus ICV colchicine group].
Figure 3: Effect of ellagic acid on mean transfer latency (TL) of rats in 
elevated plus maze paradigm. [Values are expressed as mean ± SEM (n = 6-8), 
Significance at p<0.05, aversus normal control, bversus sham control group 
and cversus ICV colchicine group].
3.3 Effect of ellagic acid on brain TBARS level
Administration of plain ellagic acid lowered the brain TBARS (p<0.05) content 





level (p<0.05) in comparison to normal control and sham control. However, 
administration of ellagic acid to ICV colchicine treated rats do not described 
increase in brain TBARS level (p<0.05). Donepezil reduced the TBARS level 
(p<0.05) in different groups of rats [Figure 4].
3.4 Effect of ellagic acid on brain GSH content
Administration of ICV colchicine reduced the GSH level (p<0.05) in brain of 
rats relative to rats of normal control and sham control. Ellagic acid (35 mg/
kg) prevented the ICV colchicine triggered diminution of brain GSH level. 
However, ellagic acid per se group rats showed no statistical difference in 
their GSH value relative to normal control rats. Moreover, donepezil enhanced 
(p<0.05) the brain GSH level in colchicine-treated groups as well as donepezil 
per se group rats [Figure 4].
3.5 Effect of ellagic acid on brain TNF-α level 
Ellagic acid (35 mg/kg) prevented (p<0.05) colchicine induced surge in 
TNF-α. There was insignificant difference between TNF-α level of normal 
control and ellagic acid per se treated groups [Figure 5].
4. DISCUSSION
ICV injection of colchicine in rats produces AD like memory deficits (15). 
In current study, the spatial learning and memory of the rats were evaluated 
by using MWM and EPM tests. Maze task performance is associated with 
Figure 4: Effect of ellagic acid on brain TBARS and GSH level of rats. [Values 
are expressed as mean ± SEM (n = 6-8), Significance at p<0.05, aversus normal 







long-term potentiation and synaptic plasticity in hippocampus and cortex (40). 
Ventrolateral frontal cortex maintains the object-information i.e. the hidden 
platform in MWM task or closed arm in EPM. Dorsolateral frontal cortex 
maintains the spatial-information i.e. the location of hidden platform or closed 
arm. Furthermore, the frontal cortex alongwith prefrontal cortex is involved in 
decision making within the working memory domain (10). The working memory 
actively maintains limited amount of information sufficient to maintain object-
information and spatial-information in maze tasks. The performance of rats in 
training trials is largely governed by working memory while that in probe trial 
by long-term memory. Perirhinal cortex, hippocampus and entorhinal cortex 
determines the acuity of spatial navigation task by rodents in maze paradigms. 
Perirhinal cortex is involved in visuoperception while hippocampus provides 
spatial map of surroundings (cognitive mapping) and along with entorhinal 
cortex it is intricately involved in path integration (27, 30).Colchicine 
selectively deposits and cause neurodegeneration in hippocampal and cortical 
regions (34, 13) thereby severely affects the working memory as well as long-
term memory of rodents during maze tasks. Acquisition of memory (learning) 
during training trials is assessed by comparing day 4 MEL vs day 1 MEL and 
retrieval of memory is assessed by day 5 TSTQ value in MWM task. A lower 
day 4 MEL indicates normal acquisition of memory and higher TSTQ indicates 
retrieval of memory. In current study, the rats treated with ICV colchicine 
showed decreased spatial learning during acquisition trials and low retrieval of 
memory i.e. higher day 4 MEL and low TSTQ value in contrast to sham control 
rats. In EPM, the memory of rodents is assessed by time consumed by animal 
Figure 5: Effect of ellagic acid on brain TNF-α level of rats. [Values are 
expressed as mean ± SEM (n = 6-8), Significance at p<0.05, aversus normal 





to locate enclosed arm starting from open arm, denoted by transfer latency 
(TL). Colchicine treatment caused increase in TL value of rats relative to sham 
control rats. Treatment with ellagic acid reduced day 4 MEL and enhanced 
TSTQ in rats that were previously administered ICV colchicine. Moreover, 
ellagic acid treatment to rats that were previously administered ICV colchicine 
showed reduction in TL value. These results comply with literaturereports, 
which revealed similar findings in response to ICV colchicine treatment (17). 
Furthermore, it was observed that plain ellagic acid enhanced the memory 
in rats in addition to its prevention of colchicine induced dementia. Ellagic 
acid per se group rats showed significantly lower day 4 MEL, higher TSTQ 
and reduced TL relative to normal control rats. These findings are dependable 
to the outcome of behavioural studies from other laboratories which signify 
the memory improving property of ellagic acid (18). Hence, ellagic acid 
ameliorated working memory in frontal cortex regions and hippocampus as 
well as retrieval of long-term memory in MTL system and neocortex of rats. 
The locomotor activity of normal control, colchicine group and ellagic acid 
per se rats showed insignificant variation. This occludes the probability that 
locomotor activity per se may have any affect during behavioural studies.
The antitubulin property of colchicine causes derangement of cellular 
microtubular functions thereby adversely affecting its metabolic machinery 
that elicits vigorous production of free radicals ultimately leading to apoptotic 
and necrotic cell death in brain of rodents (25). High oxygen consumption, 
iron content, low GSH level and utilization of glucose as obligatory energy 
source by brain further aggravates the frequency and susceptibility toward 
oxidative stress (7). Free radicals rapidly oxidize cellular polyunsaturated 
fatty acids that give rise to highly mutagenic and toxic products viz. 
malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) (2). MDA forms 
neurotoxic ‘endducts’ such as advanced lipid-peroxidation end products 
(ALEs), advanced glycation end products (AGEs), bio-molecular adducts 
(proteins and nucleic acids) and methylglyoxal-acetaldehyde adducts that 
are extremely immunogenic and cause neurodegeneration (2). MDA is a 
biomarker of lipid peroxidation and is quantified by TBARS assay. In current 
study ICV colchicine treatment amplified brain TBARS level and reduced the 
GSH content of rats. These findings are consistent with previous literature 
reports where ICV colchicine increased brain MDA level in rodents (18). GSH 
is a key thiol-antioxidant that detoxify free radicals, peroxidation products 
and preserves cellular redox status by acting as cysteine reservoir, cofactor 
for many antioxidant enzymes and directly scavenging free radicals (7). 
Failure of GSH dependent metabolization of methylglyoxal by glyoxalase 







directly correlates with aging and AD. AD patients demonstrate high brain 
as well as plasma MDA level and low GSH content relative to age matched 
controls (23, 22). MDA and GSH are two key biomarkers of oxidative stress. 
In current study, ellagic acid prevented ICV colchicine induced rise in brain 
TBARS and subsequently arrested the decline of GSH level in rodent brains. 
Moreover, ellagic acid per se group rats showed decrease in brain TBARS 
level which indicates its antioxidant potential. These findings are concordant 
with results from other researchers that emphasize the antioxidant potential 
of ellagic acid (39, 19). 
ICV colchicine triggers neuro-infammatory changes in brain, enhance COX-
2, TNF-α and other pro-inflammatory cytokine production (35). In the present 
study the brain TNF-α content of colchicine treated rats was greatly enhanced 
in comparison to the sham control rats. TNF- α plays vital role in adaptive and 
acquired immunity but microglial overactivation augments the discharge of 
pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6 (1). Chronically 
elevated brain TNF-α in AD patients (38) leads to pro-inflammatory changes 
(infiltration of leukocytes), excitotoxic neurodegeneration, overproduction 
of amyloid-β, apoptosis, necrosis, detrimental changes in lipid and glucose 
metabolism (28, 32). However, treatment of different groups of rats with 
ellagic acid for successive 25 days prevented the ICV colchicine induced rise 
in brain TNF-α level.
CONCLUSION
Ellagic acid enhanced the memory of rats against ICV colchicine induced 
oxidative stress and neuro-inflammation in rats brain. Furthermore, enhanced 
memory of ellagic acid per se group rats indicates the memory boosting 
potential of ellagic acid. 
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